Literature DB >> 12639697

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin.

Andrew V Schally1, Attila Nagy.   

Abstract

The development of targeted cytotoxic analogs of hypothalamic peptides for the therapy of various cancers is reviewed and various oncological studies on experimental tumors are summarized. Novel therapeutic modalities for breast, prostate and ovarian cancer consist of the use of targeted cytotoxic analogs of LH-RH containing doxorubicin (DOX) or 2-pyrrolino-DOX. The same radicals have been incorporated into cytotoxic analogs of somatostatin which can be also targeted to receptors for this peptide in prostatic, mammary, ovarian, renal and lung cancers, brain tumors and their metastases. A targeted cytotoxic analog of bombesin containing 2-pyrrolino-DOX has also been synthesized and successfully tried in experimental models of prostate cancer, small cell lung carcinoma and brain tumors. The development of these new classes of peptide analogs should lead to a more effective treatment for various cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639697     DOI: 10.1016/s0024-3205(03)00113-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

Review 1.  Issues related to targeted delivery of proteins and peptides.

Authors:  Yingjuan Lu; Jun Yang; Emanuela Sega
Journal:  AAPS J       Date:  2006-07-21       Impact factor: 4.009

2.  Goserelin loaded nanoparticles inhibit growth and induce apoptosis in human prostate cancer cell lines.

Authors:  Priti Tomar; Neeti Jain; G S Agarwal; V K Dixit
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

3.  Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).

Authors:  C W Kwok; O Treeck; S Buchholz; S Seitz; O Ortmann; J B Engel
Journal:  Target Oncol       Date:  2014-10-09       Impact factor: 4.493

4.  Evaluation of the Biological Properties and the Enzymatic Stability of Glycosylated Luteinizing Hormone-Releasing Hormone Analogs.

Authors:  Shayli Varasteh Moradi; Pegah Varamini; Istvan Toth
Journal:  AAPS J       Date:  2015-05-09       Impact factor: 4.009

5.  Peptide targeting of platinum anti-cancer drugs.

Authors:  Margaret W Ndinguri; Rajasree Solipuram; Robert P Gambrell; Sita Aggarwal; Robert P Hammer
Journal:  Bioconjug Chem       Date:  2009-09-23       Impact factor: 4.774

6.  Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro.

Authors:  Miklos Jaszberenyi; Andrew V Schally; Norman L Block; Marta Zarandi; Ren-Zhi Cai; Irving Vidaurre; Luca Szalontay; Arumugam R Jayakumar; Ferenc G Rick
Journal:  Target Oncol       Date:  2013-02-01       Impact factor: 4.493

Review 7.  Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Authors:  Ashutosh Barve; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

Review 8.  Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.

Authors:  Kathlynn C Brown
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

9.  Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide.

Authors:  Azade Taheri; Rassoul Dinarvand; Fatemeh Atyabi; Fatemeh Ahadi; Farank Salman Nouri; Mohammad Hossein Ghahremani; Seyed Nasser Ostad; Atefeh Taheri Borougeni; Pooria Mansoori
Journal:  Int J Mol Sci       Date:  2011-07-15       Impact factor: 5.923

10.  Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.

Authors:  Kelly K Curtis; John Sarantopoulos; Donald W Northfelt; Glen J Weiss; Kerry M Barnhart; John K Whisnant; Carola Leuschner; Hector Alila; Mitesh J Borad; Ramesh K Ramanathan
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-08       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.